The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis
Open accessAbstract
BACKGROUND: Human African trypanosomiasis (HAT) is an important public health problem in sub-Saharan Africa, affecting hundreds of thousands of individuals. An urgent need exists for the discovery and development of new, safe, and effective drugs to treat HAT, as existing therapies suffer from poor safety profiles, difficult treatment regimens, limited effectiveness, and a high cost of goods. We have discovered and optimized a novel class of small-molecule boron-containing compounds, benzoxaboroles, to identify SCYX-7158 as an effective, safe and orally active treatment for HAT. METHODOLOGY/PRINCIPAL FINDINGS: A drug discovery project employing integrated biological screening, medicinal chemistry and pharmacokinetic characterization identified SCYX-7158 as an optimized analog, as it is active in vitro against relevant strains of Trypanosoma brucei, including T. b. rhodesiense and T. b. gambiense, is efficacious in both stage 1 and stage 2 murine HAT models and has physicochemical and in vitro absorption, distribution, metabolism, elimination and toxicology (ADMET) properties consistent with the compound being orally available, metabolically stable and CNS permeable. In a murine stage 2 study, SCYX-7158 is effective orally at doses as low as 12.5 mg/kg (QD×7 days). In vivo pharmacokinetic characterization of SCYX-7158 demonstrates that the compound is highly bioavailable in rodents and non-human primates, has low intravenous plasma clearance and has a 24-h elimination half-life and a volume of distribution that indicate good tissue distribution. Most importantly, in rodents brain exposure of SCYX-7158 is high, with C(max) >10 µg/mL and AUC(0-24 hr) >100 µg*h/mL following a 25 mg/kg oral dose. Furthermore, SCYX-7158 readily distributes into cerebrospinal fluid to achieve therapeutically relevant concentrations in this compartment. CONCLUSIONS/SIGNIFICANCE: The biological and pharmacokinetic properties of SCYX-7158 suggest that this compound will be efficacious and safe to treat stage 2 HAT. SCYX-7158 has been selected to enter preclinical studies, with expected progression to phase 1 clinical trials in 2011.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ames, B. N., McCann, J., & Yamasaki, E. (1975) · Mutation Research/Environmental Mutagenesis and Related Subjects · doi:10.1016/0165-1161(75)90046-1 · Cited by 7,381
Sanguinetti, M. C., Jiang, C., Curran, M. E., & Keating, M. T. (1995) · Cell · doi:10.1016/0092-8674(95)90340-2 · Cited by 2,423
Hirumi, H., & Hirumi, K. (1989) · The Journal of Parasitology · doi:10.2307/3282883 · Cited by 1,006
Properties of HERG Channels Stably Expressed in HEK 293 Cells Studied at Physiological Temperature
Zhou, Z., Gong, Q., Ye, B., Fan, Z., Makielski, J. C., Robertson, G. A., & January, C. T. (1998) · Biophysical Journal · doi:10.1016/s0006-3495(98)77782-3 · Cited by 726
Räz, B., Iten, M., Grether-Bühler, Y., Kaminsky, R., & Brun, R. (1997) · Acta Tropica · doi:10.1016/s0001-706x(97)00079-x · Cited by 688
Self-citationRational Use of in Vitro P-glycoprotein Assays in Drug Discovery
Polli, J. W., Wring, S. A., Humphreys, J. E., Huang, L., Morgan, J. B., Webster, L. O., & Serabjit-Singh, C. S. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29270-3 · Cited by 662
Self-citationBaltz, T., Baltz, D., Giroud, C., & Crockett, J. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb03772.x · Cited by 562
Priotto, G., Kasparian, S., Mutombo, W., Ngouama, D., Ghorashian, S., Arnold, U., Ghabri, S., Baudin, E., Buard, V., Kazadi-Kyanza, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61117-x · Cited by 533
Eliminating Human African Trypanosomiasis: Where Do We Stand and What Comes Next?
Simarro, P. P., Jannin, J., & Cattand, P. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050055 · Cited by 439
Human African trypanosomiasis: pharmacological re‐engagement with a neglected disease
Barrett, M. P., Boykin, D. W., Brun, R., & Tidwell, R. R. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707354 · Cited by 338
Self-citation
Cited by
Brun, R., Blum, J., Chappuis, F., & Burri, C. (2010) · The Lancet · doi:10.1016/s0140-6736(09)60829-1 · Cited by 926
Self-citationBüscher, P., Cecchi, G., Jamonneau, V., & Priotto, G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31510-6 · Cited by 693
The animal trypanosomiases and their chemotherapy: a review
GIORDANI, F., MORRISON, L. J., ROWAN, T. G., DE KONING, H. P., & BARRETT, M. P. (2016) · Parasitology · doi:10.1017/s0031182016001268 · Cited by 447
Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)
Kennedy, P. G. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70296-x · Cited by 442
Mäder, P., & Kattner, L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00960 · Cited by 438
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need
Field, M. C., Horn, D., Fairlamb, A. H., Ferguson, M. A. J., Gray, D. W., Read, K. D., De Rycker, M., Torrie, L. S., Wyatt, P. G., Wyllie, S., et al. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.193 · Cited by 421
Grams, R. J., Santos, W. L., Scorei, I. R., Abad-García, A., Rosenblum, C. A., Bita, A., Cerecetto, H., Viñas, C., & Soriano-Ursúa, M. A. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00663 · Cited by 377
Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis
Nagle, A. S., Khare, S., Kumar, A. B., Supek, F., Buchynskyy, A., Mathison, C. J. N., Chennamaneni, N. K., Pendem, N., Buckner, F. S., Gelb, M. H., et al. (2014) · Chemical Reviews · doi:10.1021/cr500365f · Cited by 348
Management of trypanosomiasis and leishmaniasis
Barrett, M. P., & Croft, S. L. (2012) · British Medical Bulletin · doi:10.1093/bmb/lds031 · Cited by 304
Regulation of gene expression in trypanosomatids: living with polycistronic transcription
Clayton, C. (2019) · Open Biology · doi:10.1098/rsob.190072 · Cited by 282
Boron Chemicals in Diagnosis and Therapeutics
Das, B. C., Thapa, P., Karki, R., Schinke, C., Das, S., Kambhampati, S., Banerjee, S. K., Van Veldhuizen, P., Verma, A., Weiss, L. M., et al. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.38 · Cited by 279
Boron in drug design: Recent advances in the development of new therapeutic agents
Fernandes, G. F. S., Denny, W. A., & Dos Santos, J. L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.092 · Cited by 269
Metadata
- Authors
- Jacobs, R. T., Nare, B., Wring, S. A., Orr, M. D., Chen, D., Sligar, J. M., Jenks, M. X., Noe, R. A., Bowling, T. S., Mercer, L. T., Rewerts, C., Gaukel, E., Owens, J., Parham, R., Randolph, R., Beaudet, B., Bacchi, C. J., Yarlett, N., Plattner, J. J., Freund, Y., Ding, C., Akama, T., Zhang, Y.-K., Brun, R., Kaiser, M., Scandale, I., & Don, R.
- Venue
- PLoS Neglected Tropical Diseases
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-06-28
- Volume
- 5
- Issue
- 6
- Pages
- e1151
- ISSN
- 1935-2727 (ISSN-L)
- 1935-2735
- OpenAlex
- W2007025107
- Cited by
- 305
- References
- 28
- FWCI
- 17.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.